4D Molecular Therapeutics, Inc. (FDMT) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for 4D Molecular Therapeutics, Inc. (FDMT): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 50/100 — a percentile rank of 4D Molecular Therapeutics, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.
| Market cap | $764.6M |
| P / S | 8.3× |
| EV / EBITDA | -3.7× |
| Gross margin | 100.0% |
| Operating margin | -214.2% |
| Net margin | -194.7% |
| Return on equity | -44.0% |
| ROIC | -55.2% |
| Revenue growth | 278712.1% |
| Debt / equity | 0.1× |
| Dividend yield | 0.0% |
Is 4D Molecular Therapeutics, Inc. overvalued? P/S looks undervalued vs its 5-year range; P/B looks fair vs its 5-year range.
Independent of the events above — derived from 4D Molecular Therapeutics, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact